While a wide range of pharmacological treatments and disease management regimens exist to treat these conditions with varying degrees of efficacy, a promising new drug class known as glucagon-like peptide 1 receptor agonists (GLP-1s) and combination incretins such as dual GLP-1/glucosedependent insulinotropic polypeptides (GLP-1/GIPs, a subcategory of GLP-1s) has attracted widespread attention and interest from providers and patients for its potential to treat both these and adjacent conditions, and especially to drive weight loss
doi:10.1056/NEJMoa2032183.Opens in a new tab Wadden TA, Bailey TS, Billings LK, et al
Engaging in informed discussion with your healthcare provider is essential for determining whether GLP-1 therapy is appropriate for you and, if so, which specific agent best aligns with your clinical needs and personal preferences
Patients appreciate her clear, straightforward guidance and the consistency she brings to their care
Tirzepatide is a dual GLP-1/GIP receptor agonist that mimics natural gut hormones to control hunger, fullness, and blood sugar
Kuperwasser, C., Pinkas, J., Hurlbut, G.D., Naber, S.P